BRIEF-Orchard Therapeutics Says $150 Mln Strategic Financing Supports Execution Into First Half Of 2023
BRIEF-Orchard Therapeutics Says $150 Mln Strategic Financing Supports Execution Into First Half Of 2023
* ORCHARD THERAPEUTICS REPORTS 2020 FINANCIAL RESULTS AND REVIEWS RECENT ACCOMPLISHMENTS
* ORCHARD THERAPEUTICS PLC - $150 MILLION STRATEGIC FINANCING SUPPORTS EXECUTION INTO FIRST HALF OF 2023
* ORCHARD THERAPEUTICS PLC - OTL-200 U.S. FILING STRATEGY FOR METACHROMATIC LEUKODYSTROPHY (MLD) EXPECTED BY MID-2021
Source text for Eikon: Further company coverage:
((Reuters.Briefs@thomsonreuters.com;)
March 2 (Reuters) - Orchard Therapeutics PLC :
* ORCHARD THERAPEUTICS REPORTS 2020 FINANCIAL RESULTS AND REVIEWS RECENT ACCOMPLISHMENTS
* ORCHARD THERAPEUTICS PLC - $150 MILLION STRATEGIC FINANCING SUPPORTS EXECUTION INTO FIRST HALF OF 2023
* ORCHARD THERAPEUTICS PLC - OTL-200 U.S. FILING STRATEGY FOR METACHROMATIC LEUKODYSTROPHY (MLD) EXPECTED BY MID-2021
Source text for Eikon: Further company coverage:
((Reuters.Briefs@thomsonreuters.com;)
路透3月2日电-Orchard Treeutics PLC:*Orchard Treeutics报告2020年财务业绩并回顾近期成就*Orchard Treeutics PLC-1.5亿美元战略融资支持执行至2023年上半年*Orchard Treeutics PLC-OTL-200美国异色性脑白质营养不良(MLD)申请战略预计将于2021年年中完成Eikon的源文本:进一步的公司报道:(Reurs.Briefs@thomsonreurs.com;)
译文内容由第三方软件翻译。
风险及免责提示
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用浏览器的分享功能,分享给你的好友吧